Stockscreener 앱 받기
6.90
2.13%
-0.15
시간 외 거래:
6.90
전일 마감가:
$7.05
열려 있는:
$6.88
하루 거래량:
419.38K
Relative Volume:
1.53
시가총액:
$410.30M
수익:
$2.91M
순이익/손실:
$-220.40M
주가수익비율:
-1.3093
EPS:
-5.27
순현금흐름:
$-176.15M
1주 성능:
-3.77%
1개월 성능:
-29.34%
6개월 성능:
+5.99%
1년 성능:
-12.21%
1일 변동 폭
$6.755
$7.50
1주일 범위
$6.755
$7.86
52주 변동 폭
$6.1721
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
명칭
Igm Biosciences Inc
전화
650-965-7873
주소
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
IGMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
6.90 | 410.30M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-10-01 | 다운그레이드 | Truist | Buy → Hold |
| 2024-02-09 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-11-09 | 재개 | Jefferies | Buy |
| 2022-10-17 | 개시 | JP Morgan | Neutral |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2021-12-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-05 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-08-26 | 개시 | Morgan Stanley | Overweight |
| 2021-01-29 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-07-17 | 개시 | Robert W. Baird | Outperform |
| 2020-07-01 | 개시 | H.C. Wainwright | Buy |
| 2020-05-28 | 개시 | SunTrust | Buy |
| 2020-04-22 | 개시 | Wedbush | Outperform |
| 2019-10-14 | 개시 | Guggenheim | Buy |
| 2019-10-14 | 개시 | Jefferies | Buy |
| 2019-10-14 | 개시 | Piper Jaffray | Overweight |
| 2019-10-14 | 개시 | Stifel | Buy |
모두보기
Igm Biosciences Inc 주식(IGMS)의 최신 뉴스
IGM Biosciences, Inc. (NASDAQ:IGMS) CEO Mary Beth Harler Sells 1,708 Shares - MarketBeat
Igm biosciences principal accounting officer sells shares for $4,031 - Investing.com
Igm biosciences CEO sells $12,775 in stock - Investing.com
IGM Biosciences chief business officer sells shares worth $7,951 By Investing.com - Investing.com Canada
IGM Biosciences (NASDAQ:IGMS shareholders incur further losses as stock declines 21% this week, taking five-year losses to 84% - Simply Wall St
Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) Target Price at $17.75 - Defense World
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $17.75 Average Target Price from Analysts - MarketBeat
IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism - Investing.com Australia
IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism By Investing.com - Investing.com South Africa
BMO Capital Markets Begins Coverage on IGM Biosciences (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Gap Up – Here’s What Happened - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Gap UpStill a Buy? - MarketBeat
BMO Capital Initiates Coverage of IGM Biosciences (IGMS) with Outperform Recommendation - MSN
IGM Biosciences (NASDAQ:IGMS) Coverage Initiated by Analysts at BMO Capital Markets - MarketBeat
BMO sets $21 target for IGM Biosciences with Outperform rating By Investing.com - Investing.com UK
IGM Biosciences: Dizzying Number Of Pivots (NASDAQ:IGMS) - Seeking Alpha
Quest Partners LLC Decreases Stock Position in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Down 4.1%Should You Sell? - MarketBeat
How to Take Advantage of moves in (IGMS) - Stock Traders Daily
IGM Biosciences (NASDAQ:IGMS) Shares Gap DownHere's What Happened - MarketBeat
Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) Price Target at $16.13 - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Will Imvotamab Data Propel IGM Biosciences To New Heights In 2025? - RTTNews
How To Trade (IGMS) - Stock Traders Daily
FMR LLC Increases Stake in IGM Biosciences Inc - GuruFocus.com
IGM Biosciences Insiders Who Sold Avert US$165m Market Cap Dip - Simply Wall St
Biotech firm backs off its focus on oncology research - The Business Journals
IGM Biosciences (NASDAQ:IGMS) Given New $27.00 Price Target at Stifel Nicolaus - MarketBeat
Igm Biosciences: Navigating Financial Challenges Amidst Early-Stage Antibody Development - MSN
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
IGM Biosciences (NASDAQ:IGMS) Shares Down 7.8%Here's Why - MarketBeat
IGM Biosciences Inc (IGMS) Quarterly 10-Q Report - Quartz
IGM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
IGM Biosciences earnings missed by $0.21, revenue topped estimates - Investing.com UK
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
IGM Biosciences Reports $61.4M Loss, Extends Cash Runway to 2027 Despite Clinical Progress | IGMS Stock News - StockTitan
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
IGM Biosciences to Present at Three Upcoming Investor Conferences - GlobeNewswire
(IGMS) Investment Report - Stock Traders Daily
IGM Biosciences (NASDAQ:IGMS) Shares Down 3.7%Should You Sell? - MarketBeat
Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) PT at $15.00 - Defense World
IGM Biosciences (NASDAQ:IGMS) Trading 7.7% HigherHere's Why - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
IGM Biosciences' SWOT analysis: autoimmune pivot drives stock outlook - Investing.com India
Igm Biosciences Inc (IGMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):